A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holding and dividend and royalty revenue streams. Fortress works in concert with our extensive network of key opinion leaders to identify and evaluate promising products and product candidates for potential acquisition. We have executed arrangements in partnership with some of the world’s foremost universities, research institutes and pharmaceutical companies, including City of Hope National Medical Center, Fred Hutchinson Cancer Center, Dana-Farber Cancer Institute, Nationwide Children’s Hospital, Columbia University, the University of Pennsylvania, AstraZeneca plc, and Dr. Reddy’s Laboratories, Ltd.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 62M | 58M | 85M | 76M | 69M | 46M |
| Net Income | -5.3M | -56M | -69M | -95M | -65M | -47M |
| EPS | $-0.12 | $-2.69 | $-8.47 | $-239.55 | $-11.85 | $-9.75 |
| Free Cash Flow | 0 | -80M | -128M | -182M | -121M | -86M |
| ROIC | -38.9% | -68.1% | -82.3% | -70.9% | -42.7% | -30.6% |
| Gross Margin | 71.6% | 63.8% | 72.9% | 59.4% | 53.4% | 68.0% |
| Debt/Equity | 0.86 | 3.31 | 3.62 | 2.92 | 0.62 | 0.76 |
| Dividends/Share | $0.02 | $0.03 | $0.02 | $0.50 | $0.14 | $0.05 |
| Operating Income | -89M | -110M | -142M | -204M | -189M | -94M |
| Operating Margin | -143.3% | -191.4% | -168.4% | -268.8% | -274.1% | -206.7% |
| ROE | -9.6% | -246.9% | -304.6% | -226.8% | -59.5% | -46.4% |
| Shares Outstanding | 31M | 21M | 33M | 2M | 5M | 5M |
Fortress Biotech, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 63.5%. Total shareholder yield (dividends) is 0.9%.
Fortress Biotech, Inc. (FBIO) has a 5-year average return on invested capital (ROIC) of -58.9%. This is below average and may indicate limited pricing power.
Fortress Biotech, Inc. (FBIO) has a market capitalization of $75M. It is classified as a small-cap stock.
Yes, Fortress Biotech, Inc. (FBIO) pays a dividend with a trailing twelve-month yield of 0.88%.
Fortress Biotech, Inc. (FBIO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Fortress Biotech, Inc. (FBIO) reported annual revenue of $58 million in its most recent fiscal year, based on SEC EDGAR filings.
Fortress Biotech, Inc. (FBIO) has a net profit margin of -96.9%. The company is currently unprofitable.
Fortress Biotech, Inc. (FBIO) generated $-80 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Fortress Biotech, Inc. (FBIO) has a debt-to-equity ratio of 3.31. This indicates higher leverage, which may increase financial risk.
Fortress Biotech, Inc. (FBIO) reported earnings per share (EPS) of $-2.69 in its most recent fiscal year.
Fortress Biotech, Inc. (FBIO) has a return on equity (ROE) of -246.9%. A negative ROE may indicate losses or negative equity.
Fortress Biotech, Inc. (FBIO) has a 5-year average gross margin of 63.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 12 years of financial data for Fortress Biotech, Inc. (FBIO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Fortress Biotech, Inc. (FBIO) has a book value per share of $1.09, based on its most recent annual SEC filing.